Felicia Johnson, APRN
Adult Health · Conway, ARNPI 1134685217
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 183 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by Novartis at 25.7% of the total. Reporting peaked in 2024 at $829 and has fallen 62.7% since, to $309 in 2025.
Across 183 payments — averaging $16.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$759
- Merck$414
- Pfizer$311
- AstraZeneca$232
- Johnson & Johnson$163
- Amgen$147
- plus $933 from 20 others
What the payments were for
- Food & beverage$2,957100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 52 | $759 |
| Merck | 25 | $414 |
| Pfizer | 19 | $311 |
| AstraZeneca | 16 | $232 |
| Johnson & Johnson | 10 | $163 |
| Amgen | 9 | $147 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $142 |
| E.r. Squibb & Sons, L.L.C. | 7 | $125 |
| Theratechnologies Inc. | 6 | $95 |
| Sanofi-aventis U.S. LLC | 5 | $85 |
| Boston Scientific | 4 | $75 |
| Philips North America LLC | 4 | $61 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $50 |
| Lexicon Pharmaceuticals, Inc. | 2 | $42 |
| Actelion Pharmaceuticals US, Inc. | 2 | $40 |
| Scpharmaceuticals Inc. | 2 | $38 |
| Boehringer Ingelheim | 2 | $36 |
| Acadia Pharmaceuticals Inc | 1 | $24 |
| Medtronic | 1 | $20 |
| Irhythm Technologies, Inc. | 1 | $17 |
| Bayer | 1 | $16 |
| EMD Serono, Inc. | 1 | $15 |
| Neurocrine Biosciences, Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| Baxter Healthcare | 1 | $13 |
| Dexcom, Inc. | 1 | $13 |
How this compares
$2,957 in reported general payments places this provider in the 80th percentile of 154 adult health providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 169 | $126,148 |
| EntrestoSacubitril/Valsartan | 90 | $82,193 |
| XareltoRivaroxaban | 42 | $28,075 |
| BrilintaTicagrelor | 42 | $24,146 |
| Repatha SureclickEvolocumab | 32 | $23,511 |
| FarxigaDapagliflozin Propanediol | 34 | $22,949 |
| MultaqDronedarone Hcl | 18 | $17,947 |
| JardianceEmpagliflozin | 11 | $7,551 |
| Repatha SyringeEvolocumab | 13 | $7,153 |
| Ranolazine ErRanolazine | 54 | $4,477 |
| Metoprolol Succinate | 215 | $2,199 |
| Atorvastatin Calcium | 222 | $1,717 |
| Carvedilol | 249 | $1,207 |
| Ezetimibe | 28 | $1,002 |
| Bumetanide | 35 | $959 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $311 | $126,148169 claims |
| NovartisEntresto | $759 | $82,19390 claims |
| AstraZenecaBrilinta, Farxiga | $232 | $47,09576 claims |
| Johnson & JohnsonXarelto | $163 | $28,07542 claims |
| Sanofi-aventis U.S. LLCMultaq | $85 | $17,94718 claims |
| Boehringer IngelheimJardiance | $36 | $7,55111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 154 adult health providers in Arkansas.
Other adult health in Conway
- Casey BrockConway$5K
- Lane WagnonConway$4K
- Holly GainesConway$2K
- Holly MooreLittle Rock$59K
- Deborah ShipmanJonesboro$41K
- Lisa HurdJonesboro$12K
- Kari SchrankFayetteville$9K
- Amanda McClureFayetteville$9K
- Gina NullFort Smith$8K
- Darren CompasBentonville$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.